Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | RVD/KRD: 3 drug combinations as the standard frontline induction

Paul Richardson • 13 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Carfilzomib Daratumumab Dexamethasone Lenalidomide

Dr Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, highlights the superiority of 3 drug platforms and touches on why he believes there is value in saving the most effective drugs to be used after relapse. This was discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Paul Richardson

The treatment landscape for patients with multiple myeloma at first relapse 3:32
The treatment landscape for patients with multiple myeloma at first relapse
Paul Richardson • 19 Sep 2025
Advances in the research of mezigdomide for multiple myeloma: the SUCCESSOR-1 and SUCCESSOR-2 trials 3:16
Advances in the research of mezigdomide for multiple myeloma: the SUCCESSOR-1 and SUCCESSOR-2 trials
Paul Richardson • 19 Sep 2025
The impact of the Duffy null phenotype on outcomes of induction therapy in multiple myeloma 5:37
The impact of the Duffy null phenotype on outcomes of induction therapy in multiple myeloma
Paul Richardson • 19 Sep 2025
Updates from the MIDAS study: MRD-guided therapy following IsaKRD in newly diagnosed myeloma 3:25
Updates from the MIDAS study: MRD-guided therapy following IsaKRD in newly diagnosed myeloma
Paul Richardson • 13 Jun 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals